RE:RE:RE:RE:RE:RE:RE:RE:Very difficult to be constructiveGiven they expanded the board way more than they needed but did not pull anyone off, I would guess the long-timers that are nearing the end of their terms will likely not seek to be appointed again. The votes were noticeably light last year for a few of them, so that's a pretty strong indication there. If not, I and many others will probably vote the same way again. But we are a diluted group this year. Nonetheless, it serves to send a signal. It would not surprise me if other of the large new shareholders see no particular need for a huge Board in a small company, and may also want more stock-aware members or even push for knowledgible oncology types for a seat. But in the end, I'm willing to give the new financial guy on the board a shot at proving he can help. So far, he's not seen any milestones hit to take the company to the next level and perhaps get an audience, so can't really say if he's helped or not.
At this point, I'm happy to believe Marsolais and wait the 8-12 weeks to get this darn first part over the line and on to the real interesting portion of the trial. To me, it seems the dose is essentially set now and it's safe and enough to work it's wonders if the POC is valid. We'll now see if it is over a much bigger (almost 100% bigger) group of patients in a far more varied and "sortilin-positive" group than before. We just need one to work to get the AA, BTD and quick ramp to Phase 2. I just hope they ramp up recruitment and get MD Anderson and Cedars Sinai doctors on board more. This development and at least one of the conferences will be before the annual, so I'm a wait and see. Beyond that, not much we can do except see who joins for IR, see if they can actually hit a milestone or if all our hope is vanquished. If so, we've been reading the tea leaves from PL all wrong and I'd like not to think we have. Otherwise, he will be a goner as CEO and Soleus alone will make sure of that.
Scioto1 wrote:
Wino, SPCEO, others, what are your assessments? Do we have like minds to craft a simple and measurable agenda? How do we use the meeting and board elections to advance a stockholder value agenda?